TP53 and carcinoma: In general, we saw an increased frequency of multiple RAS-pathway alterations and TP53 mutations amongst carcinomas versus borderline tumors in our cohort, suggesting mutations in both of these pathways are critical in accelerating the progression of mucinous ovarian tumors.